REG - Kromek Group PLC - Full Year 2026 Trading Update

KromekAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260512:nRSL8713Da&default-theme=true

RNS Number : 8713D  Kromek Group PLC  12 May 2026

12 May 2026

 

Kromek Group plc

("Kromek", the "Company" or the "Group")

 

Full Year 2026 Trading Update

Group to report revenues and PBT in line with market expectations

 

Kromek (AIM: KMK), a global detection company focused on the advanced imaging
and CBRN detection markets, provides the following trading update for the
12-month period ended 30 April 2026 ("FY26").

 

The Group expects to report revenues and PBT for FY26 in line with market
expectations*. Results reflect increased revenue in the CBRN Detection
division and good underlying growth in the Advanced Imaging division,
excluding the exceptional contribution from the Group's enablement agreement
with Siemens Healthineers, as previously announced.

 

The Group continued to see demand across its end markets during the year, with
both divisions making further operational and commercial progress. In the
second half of the year, alongside the execution of previously secured
contracts, the CBRN Detection and Advanced Imaging divisions won new orders
totaling £8.8m, a significant proportion of which was delivered before year
end.  The Board believes that the full year performance demonstrates the
resilience of the Group's business model, the strength of its customer
relationships and the growing relevance of its technology in mission-critical
applications.

 

In the Advanced Imaging division, excluding contribution from the Siemens
Healthineers agreements, the Group continued to deliver on its long-term
contracts, achieving good underlying revenue growth. While the division faced
supply chain disruptions due to the various global trade and geopolitical
tensions, these challenges primarily affected the timing of order fulfilments.
Nonetheless, the impact of these disruptions was significantly mitigated by
securing and delivering a major new order from an existing customer in the
second half of the year. The performance of this division reaffirms the
management team's belief in the critical role of Kromek's products and
solutions in its customers' transition towards next generation photon counting
CT and SPECT scanners.

 

In the CBRN Detection division, the Group also expects to report year-on-year
revenue growth. Growth in the period was supported by continued global demand
for the Group's products and was delivered despite delays in certain
governmental contracts progressing to the procurement stage.

 

The Group ended the year with continued momentum and remains focused on
executing against its strategic priorities and continued growth across both
divisions. The Board looks forward to reporting on the Group's progress at the
time of its full year results announcement, which is expected to be in
September 2026.

 

*    The Company understands FY26 consensus estimates to be revenues of
£27.2 million and PBT of £2.15 million.

 

Enquiries

 

 Kromek Group plc
 Arnab Basu, CEO                                                        +44 (0)1740 626 060

 Claire Burgess, CFO

 Cavendish Capital Markets Limited (Nominated Adviser and Broker)        
 Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance            +44 (0)20 7220 0500

 Andrew Burdis - ECM

 Michael Johnson - Sales

 Gracechurch Group (Financial PR)
 Harry Chathli/Claire Norbury                                           +44 (0)20 4582 3500

 

Kromek Group plc

 

Kromek Group plc is a leading developer of radiation detection and
bio-detection technology solutions for the advanced imaging and CBRN detection
segments. Headquartered in County Durham, UK, Kromek has manufacturing
operations in the UK and US, delivering on the vision of enhancing the quality
of life through innovative detection technology solutions.

 

The advanced imaging segment comprises the medical (including CT and SPECT),
security and industrial markets. Kromek provides its OEM customers with
detector components, based on its core cadmium zinc telluride (CZT) platform,
to enable better detection of diseases such as cancer and Alzheimer's,
contamination in industrial manufacture and explosives in aviation
settings.

 

 In CBRN detection, the Group provides nuclear radiation detection solutions
to the global homeland defence and security market. Kromek's compact,
handheld, high-performance radiation detectors, based on advanced
scintillation and solid-state readout technology, are primarily used to
protect critical infrastructure, events, personnel and urban environments from
the threat of 'dirty bombs'.

 

The Group is also developing bio-security solutions in the CBRN detection
segment. These consist of fully automated and autonomous systems to detect a
wide range of airborne pathogens.

 

Kromek is listed on AIM, a market of the London Stock Exchange, under the
trading symbol 'KMK'.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTBRGDUIUBDGLB



            Copyright 2019 Regulatory News Service, all rights reserved